Literature DB >> 32078494

Circulating SHBG (Sex Hormone-Binding Globulin) and Risk of Ischemic Stroke: Findings From the WHI.

Tracy E Madsen1, Xi Luo2, Mengna Huang3, Ki E Park4, Marcia L Stefanick5, JoAnn E Manson6, Simin Liu7.   

Abstract

Background and Purpose- Circulating levels of SHBG (sex hormone-binding globulin) have been inversely linked to obesity, diabetes mellitus, and other cardiometabolic disorders. It remains uncertain whether low SHBG is prospectively predictive of stroke risk, particularly in women. We investigated whether SHBG is associated with risk of incident ischemic stroke (IS) among women in the WHI (Women's Health Initiative). Methods- From an observational cohort of 161 808 postmenopausal women enrolled in the WHI at 40 sites across the United States from 1993 to 1998, we identified 13 192 participants free of prevalent stroke at baseline who were included in an ancillary study that measured serum SHBG. We used Cox proportional hazards regression, stratified by SHBG measurement assay, to assess IS risk across quintiles of SHBG (Q1-Q5), adjusting first for demographic variables (model 1), additionally for body mass index, hypertension, alcohol use, and smoking status (model 2), and for physical activity and reproductive risk factors (model 3). In sensitivity analyses, potential mediators (diabetes mellitus status, levels of estradiol, testosterone, and CRP [C-reactive protein]) were included. Results- Of 13 192 participants (mean age, 62.5 years; 67.4% non-Hispanic white, 18.5% black, 7.6% Hispanic, and 5.0% Asian), after following for an average of 11.6 years, 768 IS events were adjudicated. Compared with the highest quintile of SHBG levels (referent), women in the lowest SHBG quintile had a higher risk of IS in all 3 multivariable models (model 1: hazard ratio, 1.88 [95% CI, 1.47-2.41]; model 2: hazard ratio, 1.69 [95% CI, 1.30-2.20]; model 3: hazard ratio, 1.61 [95% CI, 1.19-2.19]; trend tests P<0.05 for all models). Including potential mediators such as diabetes mellitus, estradiol, and testosterone in the models attenuated but did not eliminate significant inverse associations between SHBG and IS. Conclusions- In this prospective cohort of postmenopausal women, there was a statistically significant inverse association between serum SHBG levels and IS risk, which supports the notion that SHBG could be used as a risk stratification tool for predicting IS in women.

Entities:  

Keywords:  United States; body mass index; gonadal steroid hormones; humans; stroke

Mesh:

Substances:

Year:  2020        PMID: 32078494      PMCID: PMC7144884          DOI: 10.1161/STROKEAHA.120.028905

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  23 in total

1.  Cross-sectional association between markers of inflammation and serum sex steroid levels in the postmenopausal estrogen/progestin interventions trial.

Authors:  C Crandall; S Palla; B Reboussin; P Hu; E Barrett-Connor; D Reuben; G Greendale
Journal:  J Womens Health (Larchmt)       Date:  2006 Jan-Feb       Impact factor: 2.681

Review 2.  Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Cheryl Bushnell; Louise D McCullough; Issam A Awad; Monique V Chireau; Wende N Fedder; Karen L Furie; Virginia J Howard; Judith H Lichtman; Lynda D Lisabeth; Ileana L Piña; Mathew J Reeves; Kathryn M Rexrode; Gustavo Saposnik; Vineeta Singh; Amytis Towfighi; Viola Vaccarino; Matthew R Walters
Journal:  Stroke       Date:  2014-02-06       Impact factor: 7.914

3.  Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort.

Authors:  Sherita Hill Golden; Ann Maguire; Jingzhong Ding; J R Crouse; Jane A Cauley; Howard Zacur; Moyses Szklo
Journal:  Am J Epidemiol       Date:  2002-03-01       Impact factor: 4.897

Review 4.  Sex differences, endogenous sex-hormone hormones, sex-hormone binding globulin, and exogenous disruptors in diabetes and related metabolic outcomes.

Authors:  Simin Liu; Qi Sun
Journal:  J Diabetes       Date:  2017-01-23       Impact factor: 4.006

5.  Age, body mass, usage of exogenous estrogen, and lifestyle factors in relation to circulating sex hormone-binding globulin concentrations in postmenopausal women.

Authors:  Atsushi Goto; Brian H Chen; Yiqing Song; Jane Cauley; Steven R Cummings; Ghada N Farhat; Marc Gunter; Linda Van Horn; Barbara V Howard; Rebecca Jackson; Jennifer Lee; Kathryn M Rexrode; Simin Liu
Journal:  Clin Chem       Date:  2013-09-18       Impact factor: 8.327

6.  Sex hormone-binding globulin and risk of clinical diabetes in American black, Hispanic, and Asian/Pacific Islander postmenopausal women.

Authors:  Brian H Chen; Kathleen Brennan; Atsushi Goto; Yiqing Song; Najib Aziz; Nai-chieh Y You; Melissa F Wellons; JoAnn E Manson; Donna L White; Anthony W Butch; Simin Liu
Journal:  Clin Chem       Date:  2012-08-20       Impact factor: 8.327

Review 7.  Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.

Authors:  Eric L Ding; Yiqing Song; Vasanti S Malik; Simin Liu
Journal:  JAMA       Date:  2006-03-15       Impact factor: 56.272

8.  Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men.

Authors:  Chaoyang Li; Earl S Ford; Benyi Li; Wayne H Giles; Simin Liu
Journal:  Diabetes Care       Date:  2010-04-05       Impact factor: 17.152

Review 9.  Interactions of sex hormone-binding globulin with target cells.

Authors:  William Rosner; Daniel J Hryb; Scott M Kahn; Atif M Nakhla; Nicholas A Romas
Journal:  Mol Cell Endocrinol       Date:  2009-08-19       Impact factor: 4.102

10.  Concentrations of sex-hormone binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women.

Authors:  L Lapidus; G Lindstedt; P A Lundberg; C Bengtsson; T Gredmark
Journal:  Clin Chem       Date:  1986-01       Impact factor: 8.327

View more
  6 in total

Review 1.  The Impact of Sex and Gender on Stroke.

Authors:  Kathryn M Rexrode; Tracy E Madsen; Amy Y X Yu; Cheryl Carcel; Judith H Lichtman; Eliza C Miller
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

Review 2.  Frailty and testosterone level in older adults: a systematic review and meta-analysis.

Authors:  Xuchao Peng; Lisha Hou; Yanli Zhao; Taiping Lin; Hui Wang; Langli Gao; Jirong Yue
Journal:  Eur Geriatr Med       Date:  2022-02-02       Impact factor: 1.710

3.  Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases.

Authors:  Scott C Ritchie; Samuel A Lambert; Matthew Arnold; Shu Mei Teo; Sol Lim; Petar Scepanovic; Jonathan Marten; Sohail Zahid; Mark Chaffin; Yingying Liu; Gad Abraham; Willem H Ouwehand; David J Roberts; Nicholas A Watkins; Brian G Drew; Anna C Calkin; Emanuele Di Angelantonio; Nicole Soranzo; Stephen Burgess; Michael Chapman; Sekar Kathiresan; Amit V Khera; John Danesh; Adam S Butterworth; Michael Inouye
Journal:  Nat Metab       Date:  2021-11-08

Review 4.  Quantitative and qualitative features of carotid and coronary atherosclerotic plaque among men and women.

Authors:  Carlotta Onnis; Christian Cadeddu Dessalvi; Filippo Cademartiri; Giuseppe Muscogiuri; Simone Angius; Francesca Contini; Jasjit S Suri; Sandro Sironi; Rodrigo Salgado; Antonio Esposito; Luca Saba
Journal:  Front Cardiovasc Med       Date:  2022-09-13

Review 5.  Diet to Reduce the Metabolic Syndrome Associated with Menopause. The Logic for Olive Oil.

Authors:  Juan José Hidalgo-Mora; Laura Cortés-Sierra; Miguel-Ángel García-Pérez; Juan J Tarín; Antonio Cano
Journal:  Nutrients       Date:  2020-10-18       Impact factor: 5.717

6.  Definition, Prevalence, and Risk Factors of Low Sex Hormone-Binding Globulin in US Adults.

Authors:  Yutang Wang
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.